{"prompt": "['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 39/80', '-', 'Increase in LFT:', 'AST or ALT >8x ULN.', 'AST or ALT >3x ULN with signs of severe liver damage (i.e. with the appearance of', 'fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash and/or', 'eosinophilia [>5%], and/or total bilirubin >1.5x ULN or international normalized', 'ratio [INR] >1.5).', 'AST or ALT >3x ULN for more than 2 weeks.', 'Clinical laboratory test suggestive of cholestasis with total serum bile acid levels', '>3x ULN on a sample taken in fasted state (at least 8 hours fasted). If the routine random', 'or postprandial total serum bile acid sample is >3x ULN, then the subject should have a', 'fasted sample taken within 1 to 5 days. The results of this test will determine whether the', 'subject should discontinue IMP or not.', 'When test results need to be confirmed, the subject should return to the clinical study center', 'and be evaluated as soon as possible, preferably within 48 hours from awareness of the', 'abnormal results. This evaluation should include laboratory tests, detailed history, and physical', 'assessment. In addition to repeating AST and ALT, laboratory tests should include albumin,', 'creatine kinase, total bilirubin, direct and indirect bilirubin, gamma glutamyl transferase (GGT),', 'INR, and alkaline phosphatase. A detailed history, including relevant information, such as', 'review of ethanol, recreational drug and supplement consumption, family history, sexual', 'history, travel history, history of contact with a jaundiced subject, surgery, blood transfusion,', 'history of liver or allergic disease, and work exposure, should be collected. Further testing for', 'acute hepatitis A, B, or C infection and liver imaging (e.g. biliary tract) may be warranted. All', 'cases confirmed on repeat testing with no other cause for LFT abnormalities identified at the', \"time should be considered potential Hy's Law cases irrespective of availability of all the results\", 'of the investigations performed to determine etiology of the abnormal LFTs. Such potential', \"Hy's Law cases should be reported as SAEs.\", 'Every effort should be made to keep subjects in the study and on treatment. However, the', 'investigator can consider stopping the treatment with GLPG1690 or placebo, preferably after', \"consultation with the sponsor's study physician, in case of concerns about the subject's safety,\", 'major protocol noncompliance, serious or severe AEs or worsening of the disease condition,', \"which in the investigator's opinion needs an alternative treatment approach not being covered\", 'in the clinical study (e.g. rescue medication).', 'When study treatment is discontinued, the subject will be requested to return for the ED visit', 'and follow-up visits.', 'Subjects will be informed prior to clinical study entry that they are allowed to withdraw from', \"the clinical study. At any time and for any reason, a subject's participation in the clinical study\", 'may terminate at his/her request without prejudice to his/her future medical care. The subject', 'will be encouraged to share the reason(s) for withdrawal so this can be documented in the source', 'documents, and to complete the ED visit and follow-up visits for safety assessments, but will', 'not be obliged to do so.', 'Subjects who withdraw from the clinical study without contact with the clinical study center', '(lost-to-follow-up) should be contacted by the clinical study center so that their health status', 'can be assessed and documented in the source documents. The clinical study center should', 'make every effort to understand whether the subject is alive, including checking the medical', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 40/80', 'records, contacting general practitioner or relatives, if necessary. All attempts must be', 'documented in the source documents.', 'Subjects who discontinue IMP or the study will not be replaced.', 'The sponsor has the right to terminate the clinical study at any time in case of safety concerns', 'or if special circumstances concerning the IMP or the company itself occur, making further', 'treatment of subjects impossible. In this event, the investigator(s) and relevant authorities will', 'be informed of the reason for clinical study termination.', '4.6.', 'MEASURES TO MINIMIZE BIAS', '4.6.1. Randomization', 'At screening, subjects will be assigned a subject identification. When a subject is confirmed to', 'be eligible for the clinical study, the subject will be randomized. Allocation of each subject to', 'a given treatment will be done using a centralized electronic system (interactive web response', 'system [IWRS]). Subjects will be randomized in a 2:1 ratio to receive GLPG1690 600 mg q.d.', 'or matching placebo, respectively.', 'For each subject at each clinical study center visit, the clinical study center will contact the', 'IWRS for the appropriate treatment number to be assigned. The medication kit(s) will contain', 'the relevant IMP for the period until the next clinical study center visit.', 'Subjects and study personnel will be blinded to the treatment assigned to the subject. Additional', 'details on blinding and unblinding are provided in Section 4.6.2.', '4.6.2. Blinding and Unblinding', 'This is a randomized, double-blind clinical study. The subject and the entire clinical study team,', 'including the investigators, clinical study coordinators, and sponsor personnel are blinded to', 'treatment assignment.', 'Blinded and packaged medication will be provided to the clinical center. The placebo', 'formulation will match the active formulation in size, color, shape, and appearance. All IMP', 'formulations (active and placebo) will be packaged in the proper proportion to assure desired', 'dosages and maintenance of the blinding.', 'The blind can be broken only if the investigator deems it necessary for the safety of a subject.', 'The investigator is encouraged to discuss considerations to break the blind with the CRO', \"medical monitor (as per study contact list) or the sponsor's study physician (in case the former\", 'is not available), whenever possible and where the situation allows. However, the responsibility', 'to break the treatment code in emergency situations resides solely with the investigator. The', 'investigator is not required to discuss unblinding beforehand if he or she feels rapid emergency', 'unblinding is necessary, but is required to inform the CRO medical monitor and the sponsor in', 'a timely fashion after unblinding has occurred.', 'The blind can be broken by the investigator via IWRS.', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']\n\n###\n\n", "completion": "END"}